Stryde vs PRECICE — side by side.
Stryde was the weight-bearing successor to PRECICE 2 — the same magnetic mechanism in a stronger alloy so patients could walk on it during distraction. In February 2021 NuVasive initiated a recall — classified by the FDA as Class II (recall Z-1323-2021, posted 30 March 2021) — after reports of pain and bony abnormalities at the junction between the telescoping nail segments, later attributed to corrosion, and stopped distribution. This page is for two readers: anyone offered Stryde today, and anyone who already has one.
| Attribute | PRECICE Stryde | PRECICE 2 |
|---|---|---|
| Hardware | inside bone | inside bone |
| Cost range | — (recalled 2021) | $10,000 – $313,000 (31 clinics publishing a price) |
| Max gain (single stage) | 5–8 cm | 5–8 cm (femur), 4–7 cm (tibia) |
| Full recovery | N/A — Class II recall | 9–14 months |
| Weight-bearing | N/A | 6–10 weeks (partial), 4–5 months (full) |
| Complication rate | FDA Class II recall (February 2021): corrosion at the telescoping junction with adjacent bone changes; distribution stopped. Existing patients need periodic imaging. | No pooled cosmetic-series rate for PRECICE 2 specifically; Marwan 2020 (795 patients, 11 studies) found no statistically significant complication difference between internal nails, LON and frames. Nail-specific problems: implant failure, premature consolidation, delayed union. |
| Scar pattern | 2 small incisions per leg | 2 small (1–3 cm) incisions per leg, hip + knee |
| Pin sites | None | None |
| Popular in | Historical — discontinued worldwide | USA, Germany, UK, UAE, Israel, Italy |
| Clinics in directory | 7verified | 94verified |
What the published evidence actually supports
The FDA recall database (Z-1323-2021) records the action as Class II — a device that may cause temporary or medically reversible harm, or where serious harm is remote — initiated by the manufacturer on 12 February 2021 and posted 30 March 2021, covering 2,360 units distributed worldwide. The stated reason is complaints of pain and bony abnormalities at the interface between the telescoping segments; the manufacturer's later letters to clinicians attribute this to corrosion at the junction.
PRECICE 2 was not part of the recall. Its limitation is mechanical: the titanium nail is not rated for full weight-bearing during distraction, which is why protocols keep patients on partial weight-bearing until consolidation shows on X-ray.
How many Stryde patients developed symptomatic corrosion is not established in a single authoritative series; clinics that implanted it report their own figures, and those figures vary. Treat any single percentage you are quoted as that clinic's experience, not a population rate.
Sources are listed on each method's own page: PRECICE Stryde · PRECICE 2.
Stryde vs PRECICE — which is better?
Stryde should not be implanted anywhere in 2026; a clinic still offering it is offering a recalled device. PRECICE 2 is the nail those clinics have gone back to, with the trade-off Stryde was built to remove — restricted weight-bearing during lengthening. If you already carry a Stryde nail, the manufacturer's and FDA's guidance is periodic imaging of the junction and early removal once consolidation is complete; ask your surgeon for a written monitoring schedule rather than an assurance.
Clinics offering Stryde and PRECICE
- 3D-SurgeryMunich / Berlin
- DXB OrthopedicsDubai
- Cairo International Centre for Limb Lengthening and ReconstructionCairo
- Centre for Advanced OrthopaedicsSingapore
- Instituto DowneySeville
- Tallead Orthopedic Surgery ClinicIncheon (Yeonsu-gu, Posco Tower-Songdo 7F, 165 Convensia-daero) — note: English self-site lists Gwangmyeong, Gyeonggi